Losartan resistance
Pro Research Analysisby 
Searched over 200M research papers for "losartan resistance"
Losartan and Insulin Resistance: Mechanisms and Clinical Impact
Losartan’s Effects on Insulin Sensitivity and Resistance
Multiple studies show that losartan, an angiotensin II type 1 receptor blocker (ARB), can improve insulin resistance in various patient populations, including those with hypertension, diabetic kidney disease, and chronic heart failure 2357. In hypertensive patients with insulin resistance, losartan was more effective than benazepril (an ACE inhibitor) in lowering blood pressure and improving insulin sensitivity, as measured by HOMA-IR scores and fasting glucose levels, suggesting a potential protective effect against diabetes development . Similarly, in patients with essential hypertension and impaired fasting glucose, losartan improved insulin sensitivity more rapidly than levamlodipine besylate, though both drugs showed similar benefits after longer-term use .
Cellular and Molecular Mechanisms of Losartan’s Action
Research in cell models and clinical studies indicates that losartan’s beneficial effects on insulin resistance are linked to several molecular pathways. Losartan increases phosphorylation of Akt and its downstream targets, enhances GLUT4 translocation to the plasma membrane, and boosts glucose uptake in adipocytes. These effects are mediated through the Src/DOK1/Akt pathway, as shown by diminished benefits in Src-deficient cells . Additionally, losartan reduces oxidative stress and inflammation, as evidenced by decreased markers like 8-OHdG and nitrotyrosine, and increased antioxidant activity (SOD) in patients with diabetic kidney disease. It also modulates the PI3K pathway, increasing insulin receptor and IRS-1 protein expression while reducing IRS-1 serine phosphorylation, which is associated with improved insulin signaling .
Losartan’s Role in Inflammation and Cytokine Modulation
Losartan has been shown to decrease inflammatory cytokines such as TNF-α, IL-6, and MCP-1 in patients with chronic heart failure, and these reductions are correlated with improvements in insulin resistance . This anti-inflammatory effect may contribute to its overall benefit in metabolic regulation.
Losartan and Resistance to Its Effects
There is limited evidence directly addressing resistance to losartan itself. Most studies focus on losartan’s ability to overcome insulin resistance rather than the development of resistance to losartan’s effects. However, the improvement in insulin sensitivity appears consistent across different patient groups and conditions, with no significant reports of losartan resistance in the context of metabolic outcomes 2357.
Losartan and Vascular Resistance
In a mouse model of Marfan syndrome, losartan therapy improved glomerular structure and reduced renal vascular resistance, indicating benefits beyond glucose metabolism and suggesting a broader role in vascular health .
Losartan and Muscle Adaptation
In contrast to its metabolic benefits, losartan did not enhance muscle adaptation or hypertrophy in elderly men undergoing resistance training, indicating that its effects may be tissue- or context-specific and not universally beneficial for all forms of resistance or adaptation .
Conclusion
Losartan consistently improves insulin sensitivity and reduces insulin resistance in various clinical and experimental settings, primarily through modulation of insulin signaling pathways, reduction of oxidative stress, and anti-inflammatory effects. There is no substantial evidence of resistance to losartan’s metabolic effects, and its benefits appear robust across different patient populations. However, its effects may not extend to all physiological adaptations, such as muscle hypertrophy in the elderly.
Sources and full results
Most relevant research papers on this topic
Losartan Improves Palmitate-Induced Insulin Resistance in 3T3-L1 Adipocytes Through Upregulation of Src Phosphorylation.
Losartan improves insulin resistance in adipocytes by increasing Src phosphorylation and reducing DOK1 expression, suggesting its anti-insulin resistance ability is mediated by the Src/DOK1/Akt pathway.
DOI